Obermatt
See Similar Stocks →

Equillium

NAQ:EQ · US29446K1060
BiotechnologySmall

360° View

56
Price/Sales32
Price/Earnings67
Price/Book31
Dividend Yield1
Revenue Growth1
Profit Growth52
Capital Growth42
TSR 52w100
Leverage79
Liquidity34
Refinancing36
Combined49
Analyst Opinions100
Pro Holdings27
Opinion Changes76
Market Pulse21

Profile

CountryUSA
IndustryBiotechnology
SizeSmall
TypePublic Company
ExchangeNASDAQCM
Founded2017
Employees25
Websiteequilliumbio.com/home/default.aspx
ISINUS29446K1060
Last UpdateApr 2, 2026
Index & Theme
ImmunologyHematologyInflammationRheumatologyChronic DiseasesOncologyDermatologyGastroenterologyBiopharmaBiotechnologyLife Science

Description

Equillium, Inc., a biotechnology innovator, develops novel therapies to treat severe autoimmune and inflammatory disorders with the mission to develop life-changing therapeutics for patients. EQ504 is a preclinical-stage, novel AhR modulator that, i…

Analysis

Equillium's 360° View rank of 56 places it above its peer average — better than 56% of its true peers.

It's growing solidly (72) and on the expensive side (36). On safety it is financially sound (51), and the market shows favorable sentiment (63). Taken together, its Combined rank of 49 reads as below its peer average.

360° rank · history

1007550250
56
2026

All-time high

57

Mar 2026

All-time low

56

Jun 2026

Average rank

57

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
32
—
—
—
Price/Earnings
67
—
—
—
Price/Book
31
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
36
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Equillium with its peers
AnaptysBio
NSQ:ANAB
44
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Eledon Pharmaceuticals
NAQ:ELDN
16
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Nektar
NAQ:NKTR
4
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Relmada Therapeutics
NAQ:RLMD
—
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Adicet Bio
NAQ:ACET
26
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Rapport Therapeutics
NMQ:RAPP
13
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →